Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17020156 | 0.73 | ADORA2B (0.41) | CSNK2A1ADORA2BALDH1A1CYP17A1PDE4A | |
| SCHEMBL17008879 | 0.70 | LMNA (0.42) | CSNK2A1ADORA2BALDH1A1CYP17A1PDE4A | |
| SCHEMBL17008880 | 0.69 | TGFBR1 (0.37) | ADORA2APOLBFDPS | |
| SCHEMBL17020106 | 0.69 | CYP17A1 (0.37) | CYP17A1ADORA2AFDPS | |
| SCHEMBL17008875 | 0.68 | MAPK14 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL17008872 | 0.68 | MEN1 (0.50) | ADORA2BALDH1A1PDE4AADORA2APDE4B | |
| SCHEMBL19848361 | 0.66 | POLB (0.58) | ALDH1A1CYP17A1POLBMEN1KMT2A | |
| SCHEMBL23262015 | 0.65 | ADORA2B (0.40) | CSNK2A1ADORA2BALDH1A1CYP17A1PDE4A | |
| SCHEMBL1956056 | 0.64 | — | — | |
| SCHEMBL7333393 | 0.64 | CSNK2A1 (0.44) | CSNK2A1ADORA2BALDH1A1CYP17A1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3105207-B1 | GPR142 AGONIST COMPOUNDS | LILLY CO ELI (US) | 2018-08-22 | — | — | EP | disclosed |
| US-9861613-B2 | GPR142 agonist compounds | ELI LILLY AND COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| US-9861613-B2 | GPR142 agonist compounds | ELI LILLY AND COMPANY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170165234-A1 | GPR142 Agonist Compounds | ELI LILLY AND COMPANY | 2017-06-15 | — | — | US | disclosed |
| US-20170165234-A1 | GPR142 Agonist Compounds | ELI LILLY AND COMPANY | 2017-06-15 | — | — | US | disclosed |
| US-20170165234-A1 | GPR142 Agonist Compounds | ELI LILLY AND COMPANY | 2017-06-15 | — | — | US | disclosed |
| EP-3105207-A1 | GPR142 AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015120768-A1 | GPR142 AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015120768-A1 | GPR142 AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165234-A1 | GPR142 Agonist Compounds | GPR3, GPR142, GPR27 | CSNK2A1 1033/4885ADORA2B 872/4885ALDH1A1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.